Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Merck & Company (NYSE:MRK) on Wednesday, setting a price target of $100, which is approximately 28.37% above the present share price of $77.9.
Goldstein expects Merck & Company to post earnings per share (EPS) of $1.27 for the second quarter of 2020.
The current consensus among 12 TipRanks analysts is for a Strong Buy rating of shares in Merck & Company, with an average price target of $92.1.
The analysts price targets range from a high of $100 to a low of $84.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $12.06 billion and a net profit of $3.98 billion. The company's market cap is $196.63 billion.
According to TipRanks.com, Mizuho Securities analyst Mara Goldstein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -2.7% and a 32.87% success rate.
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services (NASDAQ:HCSG), and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca (NYSE:AZN) LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.